Search

Your search keyword '"Furuse, Junji"' showing total 11 results
Start Over Author "Furuse, Junji" Journal journal of gastroenterology
11 results on '"Furuse, Junji"'

1. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Author

Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, and Okusaka, Takuji

Published
2021
Full Text
View/download PDF

3. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

Author

Kudo, Masatoshi, Okusaka, Takuji, Motomura, Kenta, Ohno, Izumi, Morimoto, Manabu, Seo, Satoru, Wada, Yoshiyuki, Sato, Shinpei, Yamashita, Tatsuya, Furukawa, Masayuki, Aramaki, Takeshi, Nadano, Seijin, Ohkawa, Kazuyoshi, Fujii, Hirofumi, Kudo, Toshihiro, Furuse, Junji, Takai, Hiroki, Homma, Gosuke, Yoshikawa, Reigetsu, and Zhu, Andrew X.

Published
2020
Full Text
View/download PDF

5. Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Author

Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, and Okusaka, Takuji

Published
2021
Full Text
View/download PDF

6. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Author

Kudo, Masatoshi, Hatano, Etsuro, Ohkawa, Shinichi, Fujii, Hirofumi, Masumoto, Akihide, Furuse, Junji, Wada, Yoshiyuki, Ishii, Hiroshi, Obi, Shuntaro, Kaneko, Shuichi, Kawazoe, Seiji, Yokosuka, Osamu, Ikeda, Masafumi, Ukai, Katsuaki, Morita, Sojiro, Tsuji, Akihito, Kudo, Toshihiro, Shimada, Mitsuo, Osaki, Yukio, Tateishi, Ryosuke, Sugiyama, Gen, Abada, Paolo Benjamin, Yang, Ling, Okusaka, Takuji, and Zhu, Andrew Xiuxuan

Published
2017
Full Text
View/download PDF

9. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Author

Maruki, Yuta, Morizane, Chigusa, Arai, Yasuhito, Ikeda, Masafumi, Ueno, Makoto, Ioka, Tatsuya, Naganuma, Atsushi, Furukawa, Masayuki, Mizuno, Nobumasa, Uwagawa, Tadashi, Takahara, Naminatsu, Kanai, Masashi, Asagi, Akinori, Shimizu, Satoshi, Miyamoto, Atsushi, Yukisawa, Seigo, Kadokura, Makoto, Kojima, Yasushi, Furuse, Junji, Nakajima, Takako Eguchi, Sudo, Kentaro, Kobayashi, Noritoshi, Hama, Natsuko, Yamanaka, Takeharu, Shibata, Tatsuhiro, and Okusaka, Takuji

Subjects
0301 basic medicine, Original Article—Liver, Pancreas, and Biliary Tract, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, 030220 oncology & carcinogenesis, FGFR2 rearrangement, Gastroenterology, RNA sequencing, Advanced/recurrent biliary tract cancer, Fluorescent in situ hybridization
Abstract

Background Fibroblast growth factor receptor 2 (FGFR2) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However, efficient detection and the exact frequency of FGFR2 rearrangements among patients with advanced/recurrent BTC have not been determined, and the clinical characteristics of FGFR2 rearrangement-positive patients have not been fully elucidated. We aimed to determine the frequency of FGFR2 rearrangement-positive patients among those with advanced/recurrent BTC and elucidate their clinicopathological characteristics. Methods Paraffin-embedded tumor samples from formalin-fixed surgical or biopsy specimens of patients with advanced/recurrent BTC were analyzed for positivity of FGFR2 rearrangement by fluorescent in situ hybridization (FISH). RNA sequencing was performed on samples from all FISH-positive and part of FISH-negative patients. Results A total of 445 patients were enrolled. FISH was performed on 423 patients (272 patients with intrahepatic cholangiocarcinoma (ICC), 83 patients with perihilar cholangiocarcinoma (PCC), and 68 patients with other BTC). Twenty-one patients with ICC and four patients with PCC were diagnosed as FGFR2-FISH positive. Twenty-three of the 25 FISH-positive patients (20 ICC and 3 PCC) were recognized as FGFR2 rearrangement positive by targeted RNA sequencing. Younger age (≤ 65 years; p = 0.018) and HCV Ab- and/or HBs Ag-positivity (p = 0.037) were significantly associated with the presence of FGFR2 rearrangement (logistic regression). Conclusions FGFR2 rearrangement was identified in ICC and PCC patients, and was associated with younger age and history of hepatitis viral infection.

Published
2020

10. Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Author

Maruki, Yuta, primary, Morizane, Chigusa, additional, Arai, Yasuhito, additional, Ikeda, Masafumi, additional, Ueno, Makoto, additional, Ioka, Tatsuya, additional, Naganuma, Atsushi, additional, Furukawa, Masayuki, additional, Mizuno, Nobumasa, additional, Uwagawa, Tadashi, additional, Takahara, Naminatsu, additional, Kanai, Masashi, additional, Asagi, Akinori, additional, Shimizu, Satoshi, additional, Miyamoto, Atsushi, additional, Yukisawa, Seigo, additional, Kadokura, Makoto, additional, Kojima, Yasushi, additional, Furuse, Junji, additional, Nakajima, Takako Eguchi, additional, Sudo, Kentaro, additional, Kobayashi, Noritoshi, additional, Hama, Natsuko, additional, Yamanaka, Takeharu, additional, Shibata, Tatsuhiro, additional, and Okusaka, Takuji, additional

Published
2020
Full Text
View/download PDF

11. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial

Author

Kudo, Masatoshi, primary, Hatano, Etsuro, additional, Ohkawa, Shinichi, additional, Fujii, Hirofumi, additional, Masumoto, Akihide, additional, Furuse, Junji, additional, Wada, Yoshiyuki, additional, Ishii, Hiroshi, additional, Obi, Shuntaro, additional, Kaneko, Shuichi, additional, Kawazoe, Seiji, additional, Yokosuka, Osamu, additional, Ikeda, Masafumi, additional, Ukai, Katsuaki, additional, Morita, Sojiro, additional, Tsuji, Akihito, additional, Kudo, Toshihiro, additional, Shimada, Mitsuo, additional, Osaki, Yukio, additional, Tateishi, Ryosuke, additional, Sugiyama, Gen, additional, Abada, Paolo Benjamin, additional, Yang, Ling, additional, Okusaka, Takuji, additional, and Zhu, Andrew Xiuxuan, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results